Lives unaffected by cystic fibrosis


Back to the Drug Development Pipeline


Phase One

Phase One

Therapeutic Approach

Mucociliary Clearance

ARO-ENaC is a drug intended to thin airway surface liquid. It is designed to block the function of the sodium (Na+) channel found in the lungs. These channels move sodium and water away from the airway surface. Blocking these channels may help maintain fluid within the airways to improve mucus clearance.


A phase 1 study to test the safety and tolerability of ARO-ENaC is underway. The study will enroll healthy volunteers as well as adults with CF.


This program is sponsored by Arrowhead Pharmaceuticals. It is being conducted within the CFF's Therapeutics Development Network.

Contact us about ARO-ENaC >